Trial Profile
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs Adavosertib (Primary) ; Carboplatin (Primary) ; Cyclophosphamide (Primary) ; Enasidenib (Primary) ; Everolimus (Primary) ; Irinotecan (Primary) ; Lirilumab (Primary) ; Nivolumab (Primary) ; Olaparib (Primary) ; Ribociclib (Primary) ; Temozolomide (Primary) ; Topotecan (Primary) ; Vistusertib (Primary)
- Indications Brain cancer; Carcinoma; Diffuse intrinsic pontine glioma; Ependymoma; Ewing's sarcoma; Glioblastoma; Glioma; Haematological malignancies; Hepatoblastoma; Leukaemia; Malignant melanoma; Medulloblastoma; Meningioma; Nerve sheath neoplasms; Neuroblastoma; Neuroepithelial neoplasms; Neurofibromatoses; Oligodendroglioma; Osteosarcoma; Precursor cell lymphoblastic leukaemia-lymphoma; Rhabdoid tumour; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Solid tumours; Synovial sarcoma; Wilms' tumour
- Focus Biomarker; Proof of concept; Therapeutic Use
- Acronyms AcSe-ESMART; ESMART
- 05 Dec 2023 Results of arm C published in the Clinical Cancer Research.
- 26 May 2023 Planned number of patients changed from 397 to 460.
- 26 May 2023 Planned End Date changed from 1 Jan 2022 to 1 Aug 2027.